Binu Chacko
Psychiatry · Jericho, NYNPI 1265728398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 24.4% of the total. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $34.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Sunovion Pharmaceuticals Inc.$594
- Axsome Therapeutics, Inc.$490
- plus $2K from 9 others
What the payments were for
- Food & beverage$9,59899%
- Education$1101%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 63 | $2,373 |
| Otsuka America Pharmaceutical, Inc. | 48 | $1,836 |
| Alkermes, Inc. | 27 | $1,338 |
| Teva Pharmaceuticals USA, Inc. | 42 | $1,216 |
| Sunovion Pharmaceuticals Inc. | 35 | $594 |
| Axsome Therapeutics, Inc. | 6 | $490 |
| Lundbeck LLC | 24 | $370 |
| Johnson & Johnson | 6 | $350 |
| E.r. Squibb & Sons, L.L.C. | 4 | $328 |
| Corium, LLC | 14 | $258 |
| Neurocrine Biosciences, Inc. | 4 | $182 |
| AbbVie | 2 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $130 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Tris Pharma Inc | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,855
- ARISTADA$1,406
- ABILIFY MAINTENA$985
- CAPLYTA$960
- Auvelity$469
- AUSTEDO$377
- ARISTADA INITIO$351
- SPRAVATO$255
- ABILIFY ASIMTUFII$247
- Austedo XR$241
- COBENFY$125
- REXULTI$125
- INGREZZA$121
- LATUDA$117
- VRAYLAR$109
How this compares
$9,707 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 12 | $201 |
| Clonazepam | 27 | $81 |
| Escitalopram Oxalate | 12 | $35 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Jericho
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.